For a better user experience please update your browser or use Chrome or Firefox browser.
Utilities
Publication detail
HomeReport on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs
EMCDDA Risk assessments
Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs
EMCDDA Risk assessments
Publication metadata
The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in tablet form in combination with the latter and consumed as ‘ecstasy’. It has been associated, in combination with PMA, with three deaths in the EU. PMMA is devoid of any therapeutic value. Further to the conclusions of the EMCDDA risk assessment, on 28 February 2002, the Council of the European Union adopted a unanimous decision defining the new synthetic drug PMMA (para-methoxymethylamphetamine) as a substance to be placed under control measures and criminal penalties in the EU Member States.
- Published:
- Corporate author(s): European Monitoring Centre for Drugs and Drug Addiction (EU body or agency)
- Themes: Health policy , Social policy , Medical and biological research
- Subject: health policy , narcotic , new product , pharmaceutical product , pharmacology , scientific report , toxicology
|
Paper
|
|||
| ISSN 1725-4485 | ISBN 92-9168-137-7 | DOI | Catalogue number TD-44-02-844-EN-C |
- Released on EU Publications:
Document viewer
Note:
The publication cannot be displayed in the document viewer. Open web version
You may access it from: Download and languages